

Improvement of the Diagnosis and Treatment of Allergic Rhinitis in Patients with Bronchial Asthma (Molecular Genetic Analysis)

Fotima Sharipovna Iskhakova*, Nilufar Jurakulovna Khushvakova,
Gulrux Bakhtiyorovna Davronova, Abdurasul Abdukarimovich Khamidov

Samarkand State Medical Institute, Uzbekistan

Abstract In this article, the improvement of the diagnosis and treatment of allergic rhinitis in patients with bronchial asthma (molecular genetic analysis) is highlighted. It is also scientifically proven that the patient has difficulty breathing during an attack, chest tightness, swelling of the jugular veins, swelling of the face, dilation of the nostrils. In patients with bronchial asthma, a wheezing sound and wheezing are described. In addition, conclusions and recommendations for improving the diagnosis and treatment of allergic rhinitis in patients with bronchial asthma (molecular genetic analysis) are presented.

Keywords Diagnosis of bronchial asthma, Allergic rhinitis, Seizures, Wheezing, Swelling of the jugular veins, Chest pain

1. Introduction

Bronchial asthma is a chronic inflammatory disease of the respiratory tract, characterized by the following symptoms: complete or partial re-obstruction of the airways, spasm of bronchial smooth muscle, mucosal edema, infiltration of the subcutaneous layer with inflammatory cells, mucosal hypersecretion, thickening of the basement membrane; episodes of cough, wheezing, wheezing, chest tightness, which occur under the influence of special trigger factors and occur mainly in the evening or morning; respiratory hyperactivity. Bronchial asthma is one of the most common chronic diseases in childhood. In the structure of recurrent bronchopulmonary pathology, asthma accounts for 50-60% [1]. Epidemiological data show that 5-20% of children are infected with BA, according to ISAAC (International Organic Organization for Asthma and Allergy in Children). In many hands, the external disease is put on 2-6 years after the onset of the disease, which worsens the consequences of the disease.

In the etiology of bronchial asthma, two groups of factors are distinguished: antigenic and noantigenic. Antigenic factors include exogenous allergens, among which non-infectious allergens play an important role.- "domestic"

allergens (dust, epidermal, insects and insects, aquarium fish food) [2]:

- pollen allergens
- food allergens
- drugs, including gamma globulin and protein drugs.

There are clear laws of the formation of noninfectious sensitization in children. Allergodermatosis is a common form of food allergy at an early age. In some patients, the target organ in early food sensitization is the digestive tract and respiratory system. The onset of epidermal sensitization (animal hair, feather pillows, etc.) often begins concurrently with respiratory allergies, at which stage respiratory allergies occur with rhinopharyngitis, laryngotracheitis, and "minor" forms of respiratory allergies. Respiratory allergic diseases are sometimes mistakenly diagnosed as an infectious disease, which in turn leads to the use of multiple drugs and the development of drug allergies. In many children, the typical clinical picture of bronchial asthma occurs after the addition of sensitization to house dust, and its formation occurs by the age of 2-5 years of life. In children, sensitization to plant flowers is formed in adulthood, sensitization to epidermis and house dust allergens can be observed at the age of 2-5 years [3].

Asthma is also a heterogeneous disorder, and as Wenzel suggested, definitions of asthma are problematic because of its complexity, possibly reflecting a collection of different phenotypes. Most clinical definitions elaborate on the symptoms (eg, wheezing and difficulty breathing) of lung functions, of exacerbations and, often, of the response to

* Corresponding author:

fatima.ishakova@mail.ru (Fotima Sharipovna Iskhakova)

Received: May 12, 2021; Accepted: May 31, 2021; Published: Jun. 15, 2021

Published online at <http://journal.sapub.org/ajmms>

2. Materials and Methods

Heredity [8]:

1. If the child's parents do not have atopy, the risk of developing the disease in the child is 0-20%.
2. If the symptoms of atopy are present only in the father, the child develops atopic symptoms in 33% and asthma in 25%.
3. If the symptoms of atopy are present only in the mother, then atopy occurs in 48% of siblings and asthma in 38% of children.
4. If the father and mother have symptoms of atopy, then the risk of developing atopy and bronchial asthma is 60-100%.

Hypersensitivity to environmental allergens, which is ignored by the immune system of a healthy person, is inherited. In cases of hereditary predisposition to atopic diseases, BA begins at an early age and is severe. The most common cause of BA in young children is an acute respiratory viral infection with a strong sensitizing effect on the body, which affects the respiratory tract. increases the permeability of the mucous membranes to various aeroallergens, while the antigenic properties of viruses call for immunological remodeling of the macroorganism during the infectious process. In young children, for a long time, BA is replaced by "ORVI with obstructive syndrome", "recurrent obstructive bronchitis" and irrational treatment is prescribed. Many years later, the child is diagnosed with typical bronchial asthma [9]. We have shown that after antigen challenge, there is an increase in IL-5-producing T cells in the bone marrow and an increase in high-affinity IL-5 receptor, which is associated with an elevated number of eosinophil progenitors. Recently, we showed that this process is most likely due to retrograde migration of antigen-specific T cells from the airways to the bone marrow, where antigen-specific T cells can produce a number of

cytokines and help to release and differentiate the progenitor cells. Progenitor cells can be found along the entire airway in atopic individuals and can differentiate into mature eosinophils in response to local antigen challenge Figure 2) [10].

A recent meta-analysis of asthma outcomes and the treatment of rhinitis with intranasal corticosteroids failed to show any significant improvement in asthma symptoms or in lung function although a trend in favor of intranasal corticosteroids was reported. In nonasthmatic children with allergic rhinitis, intranasal corticosteroids significantly improved airway hyperresponsiveness to methacholine but had no effect on asthma symptoms. Corren and colleagues reported that intranasal corticosteroids prevent the increase of bronchial responsiveness associated with seasonal pollen exposure in allergic rhinitis patients with asthma. Other anti-inflammatory drugs (montelukast and cetirizine), when used for rhinitis patients, have also been reported to improve asthma symptoms and to decrease the use of β_2 agonists. Recent studies have reported a decrease in asthma exacerbation in patients with concomitant allergic rhinitis when these patients received any kind of rhinitis treatment. Cetirizine, an antihistamine, has shown effectiveness in relieving upper- and lower-airway symptoms in patients suffering from concomitant allergic rhinitis and asthma. Cetirizine was found to be protective against late bronchial hyperresponsiveness that follows nasal allergen challenge in patients with allergic rhinitis. Combined therapy with montelukast and cetirizine for asthmatic patients with seasonal allergic rhinitis lessens the need for a rescue inhaler and improves lung function and asthma symptom score to the same extent as does inhaled budesonide combined with intranasal budesonide. Depending on the application, the value of PSV or OFV1 depends on the daily change of PSV) [11].




Figure 2

Mechanisms that might explain the link between upper and lower airways. CNS = central nervous system.

Figure 2

Step 1: Intermediate BA [12]:

- Symptoms appear once a week.
- short repetition.
- Nocturnal symptoms occur twice a month.
- OFV1 or PSV should be 80% of the value
- The rate of PSV or OFV1 is <20%.

Step 2: Light persistent BA

- Symptoms appear once a week, sometimes once a day.
- recurrence affects physical activity, sleep.
- Nocturnal symptoms occur twice a month.
- PSV 80% of the value of OFV1 or not
- The rate of PSV or OFV1 is <20-30%.

Step 3: Medium-weight persistent BA

- Symptoms appear every day.
- recurrence affects physical activity, sleep.
- Nocturnal symptoms occur twice a week.
- daily administration of short-acting inhaled β_2 agonists;
- OFV1 or PSV 60% to 80% of the required value.
- PSV or OFV1 rate > 30%.

Step 4: Heavy persistent BA

- Symptoms appear every day.
- repetition increases.
- Nocturnal symptoms intensify.
- Physical activity is limited.
- OFV1 or PSV > 60% of the required value
- PSV or OFV1 rate > 30%

3. Results

Greiff and colleagues treated nonasthmatic allergic rhinitis patients with inhaled corticosteroids during pollen season. They found an inhibition of the increase of eosinophils in blood and nasal tissues that is usually observed in pollen season. The patients who received inhaled budesonide had significantly milder nasal symptoms. In a recent clinical study, asthmatic individuals with nasal polyposis treated with montelukast had a 70% improvement of nasal symptoms and a 60% to 90% improvement in asthma clinical score. In a study comparing treatment with montelukast alone to treatment with inhaled and intranasal corticosteroids in patients with allergic rhinitis and in patients with asthma, only the group treated with corticosteroids showed a significant reduction in nasal nitric oxide and in nasal peak flow, whereas both treatments were efficient in decreasing rhinitis symptoms [13]. Immunotherapy is reserved for patients with moderately severe allergic rhinitis. Immunotherapy reduces inflammatory-cell recruitment and activation as well as the secretion of mediators. In a group of allergic rhinitis patients with asthma, immunotherapy improved methacholine hyperreactivity and quality of life and reduced seasonal asthma symptoms. Reducing the allergen sensitivity not only leads to relief of rhinitis but also helps control asthma (although less effectively). When collecting a medical

history, the following should be considered.

- Presence of atopic dermatitis, allergic rhinoconjunctivitis, bronchial asthma or other atopic diseases in the family.

Presence of one of the following symptoms [14]:

- cough, intensified in the evening;
- repeated whistling;
- repeated episodes of difficulty breathing;
- feeling of tightness in the chest.

Occurrence or worsening of symptoms:

- at night;
- in contact with animals;
- with chemical aerosols;
- house dust;
- flower pollination;
- tobacco smoke;
- when the ambient temperature drops;
- when taking aspirin, adrenoblockers;
- after physical exertion;
- ORVI;
- after strong emotional tension;

4. Discussion

There are several conditions that may mimic asthma, such as hyperventilation syndrome or various types of glottic dysfunction, and they usually present as a paradoxical adduction of the vocal cords during inspiration [15]. These conditions are also often associated with anxiety or other psychological disturbances. Newman *et al.* reported that 56% of 95 patients fulfilling the criteria of paradoxical vocal cord motion disorder, proven with laryngoscopy, had a concomitant asthma. Hussein *et al.* reported that paradoxical vocal cord dysfunction is more common among females and older individuals, and can be a comorbidity associated with asthma, GERD and previous abuse. Psychotherapy and/or speech therapy may address the problem in such cases [16]. It is unknown whether comorbid asthma and hyperventilation syndrome or glottic dysfunction alters the long-term clinical expression of asthma. Worldwide, obesity is at epidemic levels, and there is significant morbidity associated with it. Obesity is associated with an increased prevalence of asthma, particularly among the morbidly obese and females, and a causal relationship between obesity and asthma has been suggested by recent animal and human studies. Furthermore, all studies evaluating the effects of weight loss in the obese have shown an improvement in asthma symptoms, control and medication needs. Mechanical, inflammatory and genetic/developmental factors and a higher prevalence of comorbidities have been implicated in the development of asthma in obese individuals [17].

Obesity has a major role in the development of OSA and GERD, and may theoretically act on asthma through these associated conditions. Mosen *et al.* have suggested, however,

that even after adjusting for demographics, smoking status, oral corticosteroid use and evidence of GERD, obese adults were more likely than those with a normal body mass index (BMI) to report poor asthma-specific quality of life, poor asthma control and a history of asthma-related hospitalisations. There has been a parallel increase in prevalence of obesity, OSA and asthma in the past years. The possible causal association of asthma and OSA has not, however, been systematically studied [18].

Asthma in the obese patient appears to be a specific phenotype associated with pulmonary function changes caused by breathing at low lung volumes, a systemic inflammatory process that may possibly influence airways and a reduced response to asthma medications. Thus, all of these factors combined probably explain why asthma is difficult to control in these individuals.

5. Conclusions

Numerous comorbidities are frequently associated with asthma and may influence the clinical expression and severity of asthma. They should be investigated and treated appropriately in order to determine their respective influence on asthma and improve asthma control. More research is needed to shed further light on the relationships between the various common comorbidities associated with asthma and the clinical features and outcomes of those suffering from asthma. AR and asthma often respond to the same treatments, which suggests that there is an intimate connection between the two. As a result, treatment guidelines have recognized the link between AR and asthma, and recommended that each condition be evaluated when a patient presents with either of the disorders. The guidelines further support a combined approach to treating both conditions for maximum therapy and a decreased medication load [19]. Future guidelines may even consider recommending that treatment be aimed for total or overall respiratory symptom control. This approach would address both upper and lower airway symptoms in a more comprehensive manner.

In summary, the search for treatments to improve the symptoms of patients afflicted with AR and asthma has targeted the CysLTs, one group of the many inflammatory substances in the allergic response. Research has revealed that when the CysLTs are blocked, symptoms and function improve. Steroids and antihistamines do not block the action of leukotrienes, but the LTRA montelukast is an effective blocking agent. The evidence suggests that montelukast reduces the symptoms of AR, and is comparable with antihistamines and oral decongestants; it is also effective in both SAR and PAR, and improves lung functioning in asthma. In fact, results suggest that the effectiveness increases with greater levels of allergen exposure, and efficacy is also increased when asthma symptoms are more severe. As a result, montelukast is a suggested treatment for both conditions.

REFERENCES

- [1] Skoner DP. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. *J Allergy Clin Immunol.* 2001; 108(1 Suppl): S2–8.
- [2] Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease” *Ann Allergy Asthma Immunol.* 2000; 84: 176–85.
- [3] Wenzel S. Severe asthma in adults. *Am J Respir Crit Care Med.* 2005; 172: 149–60.
- [4] Philip G, Nayak AS, Berger WE, *et al.* The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. *Curr Med Res Opin.* 2004; 20: 1549–58.
- [5] Chapman KR, Ernst P, Grenville A, Dewland P, Zimmerman S. Control of asthma in Canada: Failure to achieve guideline targets. *Can Respir J.* 2001; 8(Suppl A): 35A–40A.
- [6] Fitz Gerald JM, Boulet LP, McIvor RA, Zimmerman S, Chapman KR. Asthma control in Canada remains suboptimal: The Reality of Asthma Control (TRAC) study. *Can Respir J.* 2006; 13: 253–9.
- [7] Simons FE. Allergic rhinobronchitis: The asthma-allergic rhinitis link. *J Allergy Clin Immunol.* 1999; 104: 534–40.
- [8] Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. *J Allergy Clin Immunol.* 2000; 106(5 Suppl): S2015.
- [9] Chapman KR, Cartier A, Hébert J, McIvor RA, Schellenberg RR. The role of omalizumab in the treatment of severe allergic asthma. *Can Respir J.* 2006; 13(Suppl B): 1B–9B.
- [10] Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: How does the immune system decide to mount a helper T-cell response? *Immunology.* 2008; 123: 326–38.
- [11] Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), 2006. www.ginasthma.org Last updated: December 2007. Date last accessed: October 16, 2008.
- [12] American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. *Am J Respir Crit Care Med* 2000; 162: 2341–2351.
- [13] Chanez P, Wenzel SE, Anderson GP, *et al.* Severe asthma in adults: what are the important questions?. *J Allergy Clin Immunol* 2007; 119: 1337–1348.
- [14] Humbert M, Holgate S, Boulet LP, Bousquet J. Asthma control or severity: that is the question. *Allergy* 2007; 62: 95–101.
- [15] Bateman ED, Boushey HA, Bousquet J, *et al.* Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. *Am J Respir Crit Care Med* 2004; 170: 836–844.

- [16] Boulet L, Becker A, Bowie D, *et al.* Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD. *Can Respir J* 2006; 13: Suppl. A 5–47.
- [17] Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. *Eur Respir J* 2008; 31: 320–325.
- [18] Moore WC, Bleecker ER, Curran-Everett D, *et al.* Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. *J Allergy Clin Immunol* 2007; 119: 405–413.
- [19] Wenzel SE, Busse WW. the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. *J Allergy Clin Immunol* 2007; 119: 14–21.